In line with the ESC mission, newly presented content is made available to all for a limited time (4 months for ESC Congress, 3 months for other events). ESC Professional Members, Association Members (Ivory & above) benefit from year-round access to all the resources from their respective Association, and to all content from previous years. Fellows of the ESC (FESC), and Professionals in training or under 40 years old, who subscribed to a Young Combined Membership package benefit from access to all ESC 365 content from all events, all editions, all year long. Find out more about ESC Memberships here.
Direct comparison of high-sensitivity cardiac troponin i versus t for the early diagnosis of acute myocardial infarction
Authors : M Rubini Gimenez (Basel,CH), R Twerenbold (Basel,CH), T Reichlin (Basel,CH), B Moehring (Basel,CH), K Wildi (Basel,CH), B Meller (Basel,CH), P Haaf (Basel,CH), C Zellweger (Basel,CH), S Osswald (Basel,CH), C Mueller (Basel,CH)
M. Rubini Gimenez1
,
R. Twerenbold1
,
T. Reichlin1
,
B. Moehring1
,
K. Wildi1
,
B. Meller1
,
P. Haaf1
,
C. Zellweger1
,
S. Osswald1
,
C. Mueller1
,
1University Hospital Basel, Department of Cardiology - Basel - Switzerland
,
Purpose: The aim of our study was to compare the accuracy of high-sensitivity cardiac troponins (hs-cTn) I and T in the early diagnosis of acute myocardial infarction, as well as their utility to predict all-cause mortality.
Methods: In a prospective multicenter study we measured 2 different hs-cTn assays (hs-cTnI Abbott) and hs-cTnT Roche) and compared their diagnostic and prognostic accuracies in consecutive patients presenting to the emergency department (ED) with acute chest pain. The final diagnosis of AMI was adjudicated by two independent cardiologists using all information pertaining to the individual patient including serial measurements of hs-cTnT. Mean follow up (FU) was 24 months.
Results: Among 2211 consecutive patients, 21% had an adjudicated final diagnosis of AMI. The diagnostic accuracy as quantified by the area under the receiver-operating-characteristics curve (AUC) was slightly higher with the hs-cTnI assay (AUC 0.93; 95% confidence interval (CI) 0.92-0.94) than with the hs-cTnT (AUC 0.92; 95% CI 0.91-0.93; p = 0.078). In early presenters (<3h since chest pain onset) this difference (AUC for hs-cTnI 0.93; 95% CI 0.90-0.95; AUC for hs-cTnT 0.87; 95% CI 0.83-0.89) was much larger and highly statistically significant (p<0.001). The prognostic accuracy for all-cause mortality during FU, quantified by AUC, was significantly higher for hs-cTnT (AUC 0.79; 95% CI 0.78-0.81) as compared to hs-cTnI (AUC 0.76; 95% CI 0.74-0.77) p<0.001.
Conclusion: Both hs-cTnI and hs-cTnT provide high diagnostic and prognostic accuracy. The direct comparison revealed diagnostic superiority of hs-cTnI and prognostic superiority of hs-cTnT
In line with the ESC mission, newly presented content is made available to all for a limited time (4 months for ESC Congress, 3 months for other events). ESC Professional Members, Association Members (Ivory & above) benefit from year-round access to all the resources from their respective Association, and to all content from previous years. Fellows of the ESC (FESC), and Professionals in training or under 40 years old, who subscribed to a Young Combined Membership package benefit from access to all ESC 365 content from all events, all editions, all year long. Find out more about ESC Memberships here.
ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.
Our mission: To reduce the burden of cardiovascular disease
